These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 27100627

  • 1. Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small-cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics.
    Clarke BA, Witkowski L, Ton Nu TN, Shaw PA, Gilks CB, Huntsman D, Karnezis AN, Sebire N, Lamovec J, Roth LM, Stewart CJ, Hasselblatt M, Foulkes WD, McCluggage WG.
    Histopathology; 2016 Nov; 69(5):727-738. PubMed ID: 27100627
    [Abstract] [Full Text] [Related]

  • 2. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
    Karnezis AN, Wang Y, Ramos P, Hendricks WP, Oliva E, D'Angelo E, Prat J, Nucci MR, Nielsen TO, Chow C, Leung S, Kommoss F, Kommoss S, Silva A, Ronnett BM, Rabban JT, Bowtell DD, Weissman BE, Trent JM, Gilks CB, Huntsman DG.
    J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. SMARCA4 inactivating mutations cause concomitant Coffin-Siris syndrome, microphthalmia and small-cell carcinoma of the ovary hypercalcaemic type.
    Errichiello E, Mustafa N, Vetro A, Notarangelo LD, de Jonge H, Rinaldi B, Vergani D, Giglio SR, Morbini P, Zuffardi O.
    J Pathol; 2017 Sep; 243(1):9-15. PubMed ID: 28608987
    [Abstract] [Full Text] [Related]

  • 6. Loss of SMARCA4 Expression Is Both Sensitive and Specific for the Diagnosis of Small Cell Carcinoma of Ovary, Hypercalcemic Type.
    Conlon N, Silva A, Guerra E, Jelinic P, Schlappe BA, Olvera N, Mueller JJ, Tornos C, Jungbluth AA, Young RH, Oliva E, Levine D, Soslow RA.
    Am J Surg Pathol; 2016 Mar; 40(3):395-403. PubMed ID: 26645725
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. SMARCA4-deficient rhabdoid tumours show intermediate molecular features between SMARCB1-deficient rhabdoid tumours and small cell carcinomas of the ovary, hypercalcaemic type.
    Andrianteranagna M, Cyrta J, Masliah-Planchon J, Nemes K, Corsia A, Leruste A, Holdhof D, Kordes U, Orbach D, Corradini N, Entz-Werle N, Pierron G, Castex MP, Brouchet A, Weingertner N, Ranchère D, Fréneaux P, Delattre O, Bush J, Leary A, Frühwald MC, Schüller U, Servant N, Bourdeaut F.
    J Pathol; 2021 Sep; 255(1):1-15. PubMed ID: 33999421
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.
    Wang Y, Chen SY, Karnezis AN, Colborne S, Santos ND, Lang JD, Hendricks WP, Orlando KA, Yap D, Kommoss F, Bally MB, Morin GB, Trent JM, Weissman BE, Huntsman DG.
    J Pathol; 2017 Jul; 242(3):371-383. PubMed ID: 28444909
    [Abstract] [Full Text] [Related]

  • 11. [Small cell carcinoma of ovary, hypercalcemic type: analysis of clinicopathologic characteristics and the diagnostic utility of loss expression of SMARCA4 protein].
    Wang L, Tan C, Tu X, Zhang Y, Li X, Chang B.
    Zhonghua Bing Li Xue Za Zhi; 2015 Dec; 44(12):859-63. PubMed ID: 26888501
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Dedifferentiated and Undifferentiated Ovarian Carcinoma: An Aggressive and Molecularly Distinct Ovarian Tumor Characterized by Frequent SWI/SNF Complex Inactivation.
    Tessier-Cloutier B, Kommoss FKF, Kolin DL, Němejcová K, Smith D, Pors J, Stewart CJR, McCluggage WG, Foulkes WD, von Deimling A, Köbel M, Lee CH.
    Mod Pathol; 2024 Jan; 37(1):100374. PubMed ID: 37925057
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The value of SOX2 in the differential diagnosis of SMARCA4 (BRG1)-deficient uterine neoplasms.
    Zheng L, Zhang L, Wang XI, Katz G, Tandon N, Zhao B, Lucci J, Ding J, Zhang S.
    Hum Pathol; 2022 Jun; 124():45-55. PubMed ID: 35331811
    [Abstract] [Full Text] [Related]

  • 19. Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type.
    Lin DI, Chudnovsky Y, Duggan B, Zajchowski D, Greenbowe J, Ross JS, Gay LM, Ali SM, Elvin JA.
    Gynecol Oncol; 2017 Dec; 147(3):626-633. PubMed ID: 29102090
    [Abstract] [Full Text] [Related]

  • 20. Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
    Ramos P, Karnezis AN, Hendricks WP, Wang Y, Tembe W, Zismann VL, Legendre C, Liang WS, Russell ML, Craig DW, Farley JH, Monk BJ, Anthony SP, Sekulic A, Cunliffe HE, Huntsman DG, Trent JM.
    Rare Dis; 2014 Dec; 2(1):e967148. PubMed ID: 26942101
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.